

Mediclinic International plc
 (Incorporated in England and Wales)
 Company Number: 08338604
 LSE Share Code: MDC
 JSE Share Code: MEI
 NSX Share Code: MEP
 ISIN: GB00B8HX8Z88
 LEI: 2138002S5BSBIZTD5I60
 (“**Mediclinic**”, the “**Company**” or the “**Group**”)

26 July 2018

ANNOUNCEMENT OF THE ANNUAL GENERAL MEETING POLL RESULTS

Mediclinic announces that at its Annual General Meeting (“**AGM**”) held on 25 July 2018, all resolutions set out in the notice of the AGM were passed by the requisite majority of votes by shareholders by way of poll. The results of the poll for each resolution were as follows:

		TOTAL SHARES VOTED	% OF ISSUED SHARE CAPITAL VOTED	VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD
	ORDINARY RESOLUTIONS							
1.	To receive the Company’s financial statements and the reports by the Directors and auditors	625,083,123	84.79	625,071,801	100.00	11,322	0.00	756,974
2.	To approve the Directors’ Remuneration Report	624,930,678	84.77	584,591,036	93.54	40,339,642	6.46	909,418
3.	To declare a final dividend of 4.70 pence per ordinary share	625,551,249	84.85	625,538,743	100.00	12,506	0.00	288,848
4.	To elect Dr Ronnie van der Merwe as a Director	625,545,985	84.85	624,986,007	99.91	559,978	0.09	294,112
5.	To elect Dr Muhadditha Al Hashimi as a Director	625,545,570	84.85	625,118,233	99.93	427,337	0.07	294,527
6.	To elect Dr Felicity Harvey as a Director	625,546,210	84.85	625,119,604	99.93	426,606	0.07	293,887
7.	To re-elect Jurgens Myburgh as a Director	625,545,985	84.85	624,155,541	99.78	1,390,444	0.22	294,112
8.	To re-elect Dr Edwin Hertzog as a Director	623,687,848	84.60	607,348,527	97.38	16,339,321	2.62	2,152,247
9.	To re-elect Jannie Durand as a Director	625,264,107	84.81	612,530,823	97.96	12,733,284	2.04	575,989
10.	To re-elect Alan Grieve as a	622,786,782	84.48	621,642,338	99.82	1,144,444	0.18	3,053,315

	Director							
11.	To re-elect Seamus Keating as a Director	622,785,782	84.47	622,271,752	99.92	514,030	0.08	3,054,315
12.	To re-elect Trevor Petersen as a Director	622,786,512	84.47	620,324,982	99.60	2,461,530	0.40	3,053,585
13.	To re-elect Desmond Smith as a Director	621,209,703	84.26	551,631,116	88.80	69,578,587	11.20	4,630,393
14.	To re-elect Danie Meintjes as a Director	625,545,985	84.85	603,084,758	96.41	22,461,227	3.59	294,112
15.	To re-appoint PricewaterhouseCoopers LLP as auditors of the Company	622,507,013	84.44	618,004,417	99.28	4,502,596	0.72	3,333,084
16.	To authorise the Audit and Risk Committee to determine the remuneration of the auditors	625,265,419	84.81	624,782,389	99.92	483,030	0.08	574,678
17.	To authorise the Directors to make political donations	624,054,992	84.65	560,842,274	89.87	63,212,718	10.13	1,785,104
18.	To authorise the Directors to allot ordinary shares	625,265,198	84.81	524,756,458	83.93	100,508,740	16.07	574,899
	SPECIAL RESOLUTIONS							
19.	To authorise the Directors to dis-apply the statutory pre-emption rights	625,262,700	84.81	590,059,495	94.37	35,203,205	5.63	577,397
20.	To authorise the Directors to dis-apply pre-emption rights for purposes of acquisitions or capital investments	625,263,385	84.81	591,029,782	94.52	34,233,603	5.48	576,711
21.	To approve the reduction in minimum notice period for general meetings (other than annual general meetings)	624,328,189	84.68	602,771,765	96.55	21,556,424	3.45	1,511,908

VOTES OF SHAREHOLDERS EXCLUDING THE CONTROLLING SHAREHOLDER ON ELECTION AND RE-ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

	ORDINARY RESOLUTIONS	TOTAL SHARES VOTED	% OF ISSUED SHARE CAPITAL VOTED	VOTES FOR	%	VOTES AGAINST	%	VOTED WITHHELD
5.	To elect Dr	369,163,066	76.77	368,735,729	99.88	427,337	0.12	294,527

	Muhadditha Al Hashimi as a Director							
6.	To elect Dr Felicity Harvey as a Director	369,163,706	76.77	368,737,100	99.88	426,606	0.12	293,887
10.	To re-elect Mr Alan Grieve as a Director	366,404,278	76.20	365,259,834	99.69	1,144,444	0.31	3,053,315
11.	To re-elect Mr Seamus Keating as a Director	366,403,278	76.20	365,889,248	99.86	514,030	0.14	3,054,315
12.	To re-elect Mr Trevor Petersen as a Director	366,404,008	76.20	363,942,478	99.33	2,461,530	0.67	3,053,585
13.	To re-elect Mr Desmond Smith as a Director	364,827,199	75.87	295,248,612	80.93	69,578,587	19.07	4,630,393

Notes:

1. Any proxy appointments giving discretion to the Chairman of the Meeting have been included in the "For" total.
2. A vote "Withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.
3. The Company's total ordinary shares in issue (total voting rights) as at 25 July 2018 was 737 243 810 ordinary shares of 10 pence each. Ordinary shareholders are entitled to one vote per ordinary share held.
4. As the Company has a controlling shareholder, Remgro Limited, as defined in the Financial Conduct Authority's Listing Rules, each resolution to elect an independent non-executive director (resolutions 5 to 6 and 10 to 13) have under Listing Rule 9.2.2E been approved by a majority of the votes cast by:
 - (a) the shareholders of the Company as a whole; and
 - (b) the independent shareholders of the Company, that is, all the shareholders entitled to vote on each resolution, excluding the controlling shareholder.

In accordance with paragraph 9.6.2 of the Listing Rules, a copy of the resolutions passed at the meeting has been submitted to the National Storage Mechanism and will shortly be available for inspection at <http://www.morningstar.co.uk/uk/NSM>.

The complete poll results and details of proxy votes lodged before the AGM will be available shortly on the Investor Relations section of the Company's website at <http://ir.mediclinic.com>.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 30 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia

with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 24 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.”

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181

Media queries

FTI Consulting
Brett Pollard/Debbie Scott – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd